Introduction
Platinum compounds such as cisplatin and carboplatin are used in the treatment of several malignancies, such as testicular, bladder, lung, esophageal, gastric and ovarian cancers. Cisplatin is particularly efficacious in the treatment of testicular germ cell cancer where it can cure up to 80% of the cases (Einhorn, 2002) . On the other hand, approximately half of ovarian cancers are intrinsically resistant to cisplatin chemotherapy, and tumors initially sensitive to therapy frequently develop resistance (Ozols and Young, 1984) . The molecular basis for such extreme differences in the efficacy of platinum compounds between various cancers is unknown.
The mechanisms by which tumor cells can develop drug resistance can be arbitrarily grouped into two broad categories: (1) the mechanisms that affect the amount of damage in the DNA and, (2) the mechanisms that affect the response of the cell to this damage. Inactivation of cisplatin by glutathione S-transferase (GST) and increase in DNA repair are examples of the first type of mechanisms. Changes in cell cycle checkpoints or apoptosis through alterations of key regulatory proteins, such as p53, are examples of changes in the cell response to DNA damage. It is believed that cisplatin resistance in a given tumor arises through multiple mechanisms (Siddik, 2003) , but the relationships and interactions between the various pathways leading to resistance in cancer cells are not completely understood.
Platinum-induced apoptosis is believed to be the primary mechanism by which platinum exerts its antitumor activities. Cisplatin exposure leads to the activation of multiple molecular pathways, including the mitogen-activated protein kinase and p53 pathways (Siddik, 2003) . The p53 pathway has been shown to be generally crucial in the response to genotoxic agents, including cisplatin (Lowe et al., 1993) . DNA damages lead to the accumulation of p53 through inhibition of its ubiquitin-dependent degradation. Stabilized p53 can induce the transcription of genes important in cell cycle checkpoints, as well as genes involved in both the intrinsic and extrinsic death pathways (Ryan et al., 2001) . Interestingly, a distinct tissue specificity has been observed in the target genes regulated in response to p53 activation, suggesting the ability to fine-tune the cellular response (Sax and El-Deiry, 2003) . However, the relevance of p53 to the development of cisplatin resistance in cancer remains unclear. Indeed, in vitro experiments, as well as the study of p53 status in various sensitive and resistant tumors have yielded conflicting data (Brown et al., 1993; Eliopoulos et al., 1995; Herod et al., 1996; Wu and El-Deiry, 1996; De Feudis et al., 1997; O'Connor et al., 1997; Pestell et al., 1998 Pestell et al., , 2000 .
Gene expression profiling techniques such as microarrays and serial analysis of gene expression (SAGE) have allowed the identification of genes whose expression is acutely affected by cisplatin exposure (Amundson et al., 2005; Kerley-Hamilton et al., 2005) , as well as genes differentially expressed in cells that have developed cisplatin resistance (Sherman-Baust et al., 2003; Kang et al., 2004; Whiteside et al., 2004; Roberts et al., 2005; Cheng et al., 2006) . In addition, these techniques have also allowed for the identification of gene expression signatures that may help predict cisplatin sensitivity in various cancers (Akervall et al., 2004; Takata et al., 2005) .
In order to better understand the molecular mechanisms controlling the response of tumor cells to cisplatin exposure, as well as the mechanisms leading to cisplatin resistance, we have performed a time course of gene expression profiling of both resistant and sensitive ovarian cancer cells treated with cisplatin. We observe an extensive p53 response in both sensitive and resistant cells. We show that inhibition of the p53 pathway in the resistant cells can sensitize these cells to cisplatin. We also identified a large number of genes differentially expressed between sensitive and resistant cells, providing clues for possible mechanisms of resistance. Interestingly, connexin 43 (Cx43) was highly elevated in cisplatin-resistant cells and inhibition of the function of this protein led to an increase in drug resistance. Clearly, a better understanding of the molecular response to cisplatin may allow for improved therapy and possibly strategies to circumvent cisplatin resistance (Wernyj and Morin, 2004) .
Results

Gene expression profiling of cisplatin treatment
In order to identify genes that are altered by cisplatin treatment, we performed gene profiling on cisplatinresistant (ACRP) and -sensitive (A2780) cells using the Agilent 44K whole genome oligo microarrays. Cells were treated with cisplatin and examined for gene expression changes after 2, 6, 16 and 24 h of exposure. These time points were chosen to investigate the molecular changes that occur during cisplatin exposure, without extending our analysis to later time points where apoptosis becomes significant and may mask cisplatin-dependent gene expression changes. Multidimensional scaling (MDS) revealed that cisplatin treatment has a major effect on gene expression patterns of both cell lines at all time points (Figure 1 ). In addition, the MDS plot shows that gene expression of A2780 and ACRP cell lines in response to cisplatin treatment was relatively similar, especially at later time points (16 and 24 h).
Kinetics of gene expression changes: analysis of upregulated genes Following the initial exposure to cisplatin, cells exhibited a striking series of gene expression changes. A set of 33 of upregulated genes was detected within 2 h following treatment (Figure 2a) . Although a few of these genes were upregulated at later time points, the vast majority of these genes, representing the largest and central cluster in Figure 2a , were back to basal level at later times. These genes included FOS and EGR1, which have previously been shown to be involved in cisplatin response (Moorehead and Singh, 2000; Thiel and Cibelli, 2002) .
The list of genes upregulated at 6 h comprised very few genes from the 2 h time point or from later time points. The genes that were found elevated at 6 h posttreatment were generally poorly characterized genes and had more disparate expression patterns. It is also noteworthy that only 14 genes met the criteria for selection at this time point.
By 16 h of treatment, a major pattern of gene expression was beginning to emerge. Interestingly, as shown in Figure 2c , the 16 h genes (36 genes total) organized into a major cluster which exhibited a striking gene expression pattern: these genes were not upregulated before at the 2 or 6 h time points, but maintained their high level of expression at 24 h, suggesting the establishment of a large gene expression program in response to cisplatin exposure. By 24 h, a large number of genes (total of 106) were included in this cluster ( Figure 2d ) and appeared to represent a p53-dependent cluster with many genes known to be p53-responsive, such as CDKN1A (p21), BBC3 (PUMA), DDB2, TP53I3 (PIG3) and many others. The list of genes upregulated after 24 h of treatment is extensive and includes genes involved in DNA damage response and repair (DDB2, SESN1, POLH, RAD52B, BTG2, GAD-D45A), cell cycle control (CDKN1C, CDKN1A, PLK3, PLK2, CCNG1, TOB1, SEPT6, SULF2, MT1E, MT2A), energy regulation/metabolism (TAP1, PPM1D, PRKY, FDXR, APOBEC3C APOBEC3C), and apoptosis (RNF34, TP53I3).
Kinetics of gene expression changes: analysis of downregulated genes
In general, fewer genes were downregulated at the various time points, compared to the number of genes upregulated. In addition, genes downregulated tended to be poorly characterized, often represented by expressed sequence tags or hypothetical proteins. Overall, the clusters were not as tight, indicating a lack of a coordinated transcriptional response.
A total of 15 genes were downregulated at 2 h following treatment with cisplatin (Figure 2e ), 11 after 6 h (Figure 2f ), 17 after 16 h (Figure 2g ) and 13 after 24 h (Figure 2h) . Contrary to what we observed with upregulated genes, the genes at 16 and 24 h were mostly different, with only BC030122, a gene of unknown function, down at both time points (it was also down at 2 h). Three genes downregulated at 2 h (AF278760, NSF, IL-22) were also found downregulated at 6 h. Interestingly, many of the genes found downregulated at 24 h are involved in cytoskeleton formation and/or regulation (TAGL, ACTA2, ACTG2, COTL1, MAPT).
Genes differentially expressed in cisplatin-resistant cells We next sought to identify genes that were consistently differentially expressed between A2780 and ACRP, regardless of cisplatin exposure. The gene identification process took into account the level of changes, as well as consistencies among all time points as described in Materials and methods. Table 1 lists genes upregulated more than threefold in ACRP compared to A2780. GJA1, a gene encoding a gap junction protein (Cx43), was the most highly elevated gene in ACRP compared to A2780. COL11A1, HAPLN1 and PEG10, three genes previously identified by SAGE (Sherman-Baust et al., 2003) as upregulated in cisplatin resistance were also found using Agilent oligo microarrays. Genes downregulated were also identified and those decreased more than fivefold compared to A2780 are indicated in Table 2 . Differentially expressed genes from these two tables were analysed using the gene ontology program InGenuity (www.ingenuity.com). Fifteen of the 86 genes fell in the broad category 'cellular growth and proliferation, organ development, cancer' (data not shown). No other categories had more than one gene present.
Real-time reverse transcription-polymerase chain reaction analysis of selected candidates In order to validate our oligoarray analyses, we performed real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis on randomly selected genes. CDKN1A (p21), DDB2, BBC3 (PUMA) and TP53I3 (PIG3) have all been shown to be controlled by p53 and were chosen for real-time PCR analysis. The expression patterns obtained by PCR were remarkably similar to those obtained with oligoarrays, with little or no overexpression at early time points but highly elevated expression at 16 and 24 h following cisplatin exposure (Figure 3a) . Similarly, two genes (EGR1, FOS) that were identified as early responders to cisplatin treatment (2 h) were investigated by RT-PCR. Again, the patterns were extremely similar to the oligoarray results ( Figure 3b) . Other 2 h time-point genes, however, fail to reach significance in the validation step, suggesting that the changes at this time point are extremely small and may not be as reproducible as the robust p53 induction. We next validated five genes from Table 1 that are highly elevated in ACRP compared to A2780. MGST1, PEG10, CYP1B1, TFPI2 and TWIST1 were all found to be highly elevated at all time points in ACRP compare to A2780 (Figure 3c ). As previously reported in several studies, the absolute fold overexpression levels as measured by microarray and RT-PCR were not identical, but the trends were conserved.
Cx43 in the development of cisplatin resistance According to our oligoarray experiments, GJA1 (encoding Cx43) was the most highly upregulated gene in ACRP compared to A2780 (Table 1) . Immunoblotting using a Cx43-specific antibody showed that this protein was highly elevated (Figure 4a ). Similarly, immunofluorescence confirmed a high level of expression of Cx43 in ACRP compared to A2780, where very few cells appeared to express the protein (Figure 4b ). The scrape/dye transfer assay for gap junction function showed an increased level of dye transport in ACRP cells, consistent with the presence of Cx43 in these cells ( Figure 4c ). In order to test whether Cx43 has a direct role in cisplatin resistance, we used the gap junction inhibitor 18a-glycyrrhetinic acid (a-GA). Gap junction inhibition in A2780 had little effect on cell survival following cisplatin treatment ( Figure 4d ). However, a-GA treatment of ACRP cells, which express high levels of Cx43 and exhibit gap junction activity, led to a significant increase in cisplatin resistance ( Figure 4d ). Interestingly, this effect was only observable when cells were plated at high density, again suggesting a role for gap junctions in this phenomenon.
Role of p53 pathway in cisplatin sensitivity
Because we find that the p53 pathway is induced following cisplatin treatment, we next examined the importance of this pathway on cisplatin sensitivity in our model. The p53 coding region was sequenced and was found to be wild-type in both cell lines (data not shown). P53 protein level was highly elevated at 16 and 24 h (Figure 5a ), which corresponded exactly to the induction of p53-responsive genes in our microarray. In order to investigate the role of the p53 pathway in cisplatin sensitivity, we used RNA interference technology to inhibit this pathway. Treatment of ACRP or A2780 cells with p53 small interfering RNA (siRNA) led to a significant decrease in the expression of p53 in both the presence and absence of cisplatin treatment ( Figure 5b ). It is worth noting, however, that p53 was still induced by cisplatin treatment, albeit at much lower levels. Accordingly, the p21 induction that was observed in the presence of cisplatin was greatly reduced in cells when p53 was knocked down. Interestingly, although p53 knockdown did not significantly affect cisplatin 
b Figure 2 Hierarchical clustering of gene expression in response to cisplatin exposure. Clustering of genes upregulated at 2 h (a), 6 h (b), 16 h (c) and 24 h (d) as well as genes downregulated at 2 h (e), 6 h (f), 16 h (g) and 24 h (h) are shown. Clustering was performed using the Dchip software (Li and Wong, 2001) , and genes elevated compared to the initial reading (time 0) are shown in red, whereas genes that are decreased are indicated in blue. The main gene cluster discussed in the text, the p53 cluster, is indicated by a thick vertical line.
survival in A2780 cells (Figure 5c ), p53 inhibition led to an average 2.5-fold decrease (at 8 mM cisplatin) in the number of surviving colonies in the cisplatin-resistant ACRP cells (as measured through automated colony counting) (Figure 5d ). The decrease in colony number was also obvious at 6 mM cisplatin treatment, although accurate colony counts could not be obtained because of the large number of surviving colonies.
Discussion
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Cisplatin treatment in ovarian cancer cell J Li et al A2780 and ACRP are relatively different in terms of gene expression. Following cisplatin treatment, these lines became progressively more similar, probably because of an extensive p53 response at these later time points. However, we were still able to identify a significant number of genes that are differentially expressed at all time points between these lines (see Tables 1 and 2 ). The time course of cisplatin gene expression response reveals many different interesting points. First, there are a number of genes induced as early as 2 h following exposure, including FOS and EGR1, which were validated by RT-PCR. Second, the 6-h time point appears to be an 'in-between' time where most of the 2-h genes are back to basal levels and before the p53 response has been initiated. Only 14 genes are upregulated at 6 h and none of these genes are tightly clustered together, indicating a lack of coordinated expression. Third, at 16 and 24 h of exposure we observe a strong p53 response in both cell lines with tight clusters containing many known p53-responsive genes. This finding is similar to a previous study reporting a major p53 response in cisplatin treatment and identified many p53-controlled genes (Kerley-Hamilton et al., 2005) . Interestingly, a large number of genes are common between the above study and our 24 h time point list. Fourth, there are overall very few downregulated genes at any time points and the downregulated genes do not tightly cluster suggesting a lack of coordinated regulation. Therefore, the adaptive response to cisplatin seems to mostly occur through gene induction (either through transcriptional activation or RNA stabilization) rather than gene downregulation. In addition, the downregulated genes were much more likely to be unknown or poorly characterized genes. Finally, among the genes downregulated after 24 h, many encode cytoskeletal proteins. A link between cisplatin exposure and cytoskeletal alterations has been reported (Kopf-Maier and Muhlhausen, 1992; Shen et al., 2004) .
Our results present an extensive list of genes that are associated with a p53 response to cisplatin exposure, and therefore provide a map of a cisplatin-dependent p53 transcriptional response. Whereas many of these genes are known to be p53 targets, many others are not and may represent novel targets for p53 transcriptional activity, at least in cisplatin response. The gene list provided here, together with the results published recently by Kerley-Hamilton et al. (2005) may provide a basis for a better understanding of the p53 response to cisplatin. However, approximately 50% of ovarian tumors have a mutated p53 gene and will therefore respond quite differently to cisplatin treatment. Indeed, it has been shown that knockdown of p53 before drug treatment will abolish the p53 component of the gene expression profiles seen in cisplatin-treated germ cell tumors (Kerley-Hamilton et al., 2005) . It will be interesting to compare the details of the cisplatininduced transcriptional responses of ovarian cells containing wild-type and mutant p53, as p53 status has been reported to be predictive of chemotherapy Cisplatin treatment in ovarian cancer cell J Li et al response in several studies (Buttitta et al., 1997; Dong et al., 1997; Reles et al., 2001) . Our siRNA experiments show that p53 knockdown led to a decrease in drug resistance in our ACRP cells but not in the parental sensitive A2780 cells (Figure 5c ). This suggests that the development of cisplatin resistance in ACRP cells may be related to the p53 response. In particular, some crucial p53 targets may be slightly different in ACRP compared to A2780. The fact that p53 inhibition decreases cisplatin resistance in ACRP is consistent with previous observations showing that p53 inactivation leads to increased sensitivity to cisplatin (Hawkins et al., 1996; Koivusalo et al., 2002) and other chemotherapeutic drugs (Hawkins et al., 1996; Bunz et al., 1999) . The relatively small effect we observe in our system may be due to the incomplete inhibition of p53 expression. Whereas p53 has an important role in promoting apoptosis, it also plays an important role in cell cycle arrest, allowing repair of the damage and our observation in ACRP cells are consistent with this fact. In the absence of this crucial checkpoint, it is conceivable that cisplatin-treated cells simply undergo catastrophic cell divisions, from which they cannot recover. The reasons why the survival of A2780 cells is not affected by p53 inhibition is unclear but may be related to different downstream effects of p53 in these cells, perhaps because of slight differences in the p53 targets in these cells. We are currently trying to identify specific p53 targets that may be responsible for the difference in the p53 response we observe between A2780 and ACRP.
In addition to slight changes in the p53 response as suggested above, the differences in cisplatin sensitivity of A2780 and ACRP may be due to differences in the molecular circuitry of these cells and that, although their acute response to cisplatin treatment is similar, the ultimate survival outcome is different. This is consistent with the fact that we find a large number of genes that are differentially expressed between ACRP and A2780 before contact with cisplatin.
Although the functions of the genes upregulated in cisplatin resistance are varied, many of the genes identified encode secreted or membrane proteins. This is in agreement with our previous findings using SAGE (Sherman-Baust et al., 2003) , and suggests that cells may remodel their microenvironment to favor drug , genes that are activated after 2 h cisplatin treatment (b) and genes that are upregulated in ACRP compared to A2780 (c). In each graph, A2780 and ACRP are represented by light and dark bars, respectively. For each individual gene, the expression levels at different time points were normalized to control (A2780, 0 h sample). In addition, the relative expression levels are normalized to GAPDH expression. Each gene was amplified in duplicate and each experiment was performed three times. The s.e. of measurement is shown and the asterisks indicate statistically significant changes.
Cisplatin treatment in ovarian cancer cell J Li et al resistance, as has previously been suggested (Dalton, 1999; Morin, 2003) . In addition, we find that MGST1 is elevated in ACRP, consistent with a long-held theory that the glutathione detoxification pathway plays an important role in cisplatin resistance (Kartalou and Essigmann, 2001) . Interestingly TWIST1, a potential oncogene (Maestro et al., 1999) is another gene we find elevated in cisplatin-resistant cells, and has been reported to be involved in acquired resistance to taxol (Wang et al., 2004) . We also identified several genes downregulated in cisplatin-resistant cells (Table 2) , including GPC3, a gene previously suggested to be a tumor suppressor in ovarian cancer (Lin et al., 1999) . Varma et al. (2005) also found GPC3 downregulated in cisplatin-resistant ovarian cells. GPC3 loss may therefore provide increased resistance and this finding may explain the relatively frequent downregulation of GPC3 in various cancers (Filmus, 2001) . The tables of differentially expressed genes in cisplatin-resistant cells provide a large number of candidate genes that may play a significant role in the development of resistance. A careful analysis of these genes in vitro and in vivo will be crucial in determining which ones are relevant and might become target for therapy. However, it is important to emphasize that the exact mechanisms of resistance, and therefore the associated changes in gene expression may be tumor specific. This fact is highlighted by the observation that there is overall little overlap in the genes identified in different gene expression profiling studies of cisplatin resistance. In addition, a recent study shows that no genes were found differentially expressed in all six pairs of sensitive/resistant cell lines studied using cDNA microarrays (Cheng et al., 2006) . It will be important to clarify whether this variability in gene expression is due to fundamentally different mechanisms of drug resistance, or simply due to downstream variability in the gene expression patterns resulting from a small number of basic resistance processes. GJA1 was identified as one of the most highly upregulated genes in ACRP compared to A2780. Immunoblotting and immunofluorescence confirmed that Cx43 was highly upregulated at the protein level in ACRP cells compared to A2780. However, inhibition gap junction function by a-GA led to an increase in drug resistance in ACRP. This finding is consistent with reports that overexpression of Cx43 in ovarian cancer cells can sensitize these cells to drug treatment (Fernstrom et al., 2002) , and fits in the overall model that gap junction may have a role in transmitting the cell damage or death signals to neighboring cells, thereby causing a 'bystander' effect (Azzam et al., 1998; Tanaka et al., 2001 ). More difficult to explain is the fact that Cx43 is highly elevated in our cisplatin-resistant cell line ACRP, although Cx43 overexpression has been reported in cells subjected to various stresses (Azzam et al., 2003) . There have been conflicting reports on the roles of gap junction proteins in cell survival. As discussed above, gap junctions have been implicated in the bystander effect, but gap junction proteins, such as Cx43, have also been shown to be important in cell survival (Lin et al., 2003) . Intriguingly, this survival effect appeared to be independent of gap junction formation, so it is clearly possible that Cx43 may have two opposite effects on cell survival, one depending on gap junction formation and the other on a poorly characterized survival function of the protein. The ultimate effect of Cx43 on drug resistance may depend on the conditions during the development of drug resistance or during the exposure of drug-resistant cells to cisplatin. Although the selection of cisplatin resistance may have favored cells that express high levels of Cx43, continued expression of this gene may decrease drug resistance by promoting a bystander effect. These aspects of Cx43 function in drug resistance are currently under investigation. In any case, because of the vast difference in Cx43 levels in the ACRP resistant cells, and because of the effects on resistance caused by the inhibition of this protein, it is clear that Cx43 plays a role in drug sensitivity. We report a comprehensive time-course study of cisplatin response in a pair of ovarian cell lines with varying sensitivity to cisplatin. We report a striking p53 signature in both cell lines, and we show that the p53 response is functionally significant in cisplatin resistance. Furthermore, we have identified several genes differentially expressed between resistant and sensitive cells providing candidates for functionally investigating the mechanisms involved in the development of cisplatin resistance. These types of analyses may lead to novel approaches for the development of therapy aimed at reversing or decreasing drug resistance.
Materials and methods
Cell culture and RNA preparation The cisplatin-sensitive serous adenocarcinoma cell line A2780 was generously provided by Dr Vihelm Bohr (National Institute on Aging, Baltimore, MD, USA). This cell line was used to generate the cisplatin-resistant cell line ACRP (ShermanBaust et al., 2003) , and both the drug resistant derivative and the parental cells have wild-type p53. ACRP cells have an IC 50 for cisplatin killing of approximately 3 mM, compared to 0.75 mM for A2780. ACRP cells are cross-resistant to taxol (slightly) and doxorubicin, but the exact mechanisms of resistance are unknown. Both cell lines were maintained in Roswell's Park Memorial Institute medium supplemented with 10% fetal bovine serum, antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) and 4 mg/ml bovine insulin (Invitrogen Life Technologies, Carlsbad, CA, USA). For RNA preparation, the cells were cultured to 50% confluence and treated with 3 mM cisplatin (Sigma-Aldrich, St Louis, MO, USA) for 0, 2, 6, 16 and 24 h. Total RNA was isolated using TRIZOL reagent (Invitrogen Life Technologies) according to the manufacturer's instruction. The quality of the RNA was assessed by agarose gel.
Agilent whole genome oligo microarray Total RNA was labeled using Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Palo Alto, CA, USA) following the manufacturer's instruction. Briefly, 2 mg RNA was used for cDNA synthesis followed by fluorescent cRNA synthesis. All samples were labeled with cyanine 3-CTP (Perkin Elmer Life Sciences, Boston, MA, USA) during fluorescent cRNA synthesis, A2780 0 h sample was also labeled with cyanine 5-CTP (Perkin Elmer Life Sciences) as a reference for each individual sample. Following labeling, each cyanine 3-labeled cRNA (750 ng) was combined with cyanine 5-labeled reference cRNA (750 ng), hybridization to Agilent Human Whole Genome (44K) Oligo Microarrays (Agilent Technologies) was performed using Agilent In situ Hybridization Kit Plus according to the manufacturer's instruction. Slides were scanned using the Agilent Microarray Scanner (model G2565B).
Microarray analysis
Raw pixel densities were imported to Excel spreadsheet for analyses. Spots with intensities smaller than 300 at all time points were excluded from the analysis, and the resulting data were used for MDS analysis using the NHGRI in-house suite of microarray software analysis tools (http://www.arrayanalysis. nih.gov). Briefly, ratios of experimental to control intensities were calculated, cutoff measurements were applied and the ratio intensity file was subjected to preprocessing. Reprocessing consisted of z-score calculations normalized around the gene intensity, and this was submitted for linear discriminant analyses, from which an MDS plot was generated. To identify genes that were differentially expressed at different time points the following procedures were used: (1) to identify genes elevated at 2 h following cisplatin exposure, genes that were induced more than 1.8-fold at 2 h compared to 0 h in both cell lines, were chosen for clustering. The same procedure was used to identify genes upregulated at 6, 16 and 24 h post-cisplatin exposure, as well as the genes downregulated at the different time points. Once the genes were identified, they were clustered using the software Dchip (Li and Wong, 2001) , which was also used for the generation of heat maps representing gene expression at various time points. In order to identify genes that were differentially expressed between A2780 (cisplatinsensitive) and ACRP (cisplatin-resistant), we first obtained a ratio of gene expression between these cell lines at each individual time points. The average of fold induction or downregulation was then averaged over all the time points and the genes were ordered accordingly. In order to avoid identifying genes that are not consistently differentially expressed across the time points, only genes with a fold induction (or downregulation) of at least 1.5 at every single time point were retained. Gene Ontology analysis was performed using the Ingenuity pathway analysis program (www.ingenuity.com).
Real-time RT-PCR
One microgram of total RNA was used to generate cDNA using the Taqman Reverse Transcription Reagents (PE Applied Biosystems, Foster city, CA, USA). The SYBR Green I assay and the 7300 Real-Time PCR System (PE Applied Biosystems) were used for detecting real-time PCR products as described previously (Hough et al., 2001) . Primers for candidate genes and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were designed to cross intron-exon boundaries to distinguish PCR products generated from genomic versus cDNA template. The primer sequences are available online as Supplementary Material. PCR reactions for each gene were performed in duplicate within each independent experiment using universal cycling parameters (one cycle of 501C for 2 min and 951C for 10 min followed by 40 cycles of 951C for 15 s and 601C for 1 min). Each PCR reaction was optimized to ensure that a single band of the appropriate length was amplified and that no bands corresponding to genomic DNA amplification or primer-dimer pairs were present. The comparative C T method (Livak and Schmittgen, 2001 ) was used to quantitate the expression for each gene relative to the A2780 (0 h sample) using GAPDH as a normalization control. PCR reactions for each individual gene were repeated three times. Student's t-test was used to determine statistical significance between cisplatin treatment and control, and between ACRP and A2780.
siRNA knockdown, Cx43 inhibition and clonogenic assays P53 siRNA (siRNA ID no. 42852) was purchased from Ambion Inc. (Austin, TX, USA) and control siRNA rhodamine conjugate (catalog no. 1022083) from Qiagen (Germantown, MD, USA). Cells were transfected with 100 nM siRNA using LipofectAMINE 2000 (Invitrogen) following manufacturer's instructions. Mock and nonspecific siRNA transfections were used as negative controls. Cells were replated after 24 h transfection. Approximately 24 h later, 50% confluent cells were treated with cisplatin (at 4, 6 and 8 mM for both A2780 and ACRP) for 16 h. The drug was removed and surviving cells were left to form colonies. Whole-cell lysates were also prepared for immunoblot analysis. In order to test the role of Cx43 in cisplatin resistance, cells were cultured to 80-90% confluence to allow gap junction formation, pretreated with 75 mM of the gap junction inhibitor a-GA (SigmaAldrich) for 1 h, and treated with cisplatin for 16 h in the absence or presence of a-GA (cells became confluent shortly after cisplatin treatment). The cells were then left to form colonies. Each treatment was performed in triplicate and the experiment was repeated twice. Colonies were stained with 0.5% crystal violet in 50% methanol for 5 min, washed with water and allowed to dry. Images of the plates were obtained using a HP scanner Scanjet 4400c and the colonies were counted using the ImageJ Software (http://rsb.info.nih.gov/ij/).
Immunoblotting
Cells were cultured to 50-80% confluence, washed with Hank's balanced salt solution (HBSS) (Invitrogen Life Technologies) and whole-cell lysates were made using lysis buffer: 62.5 mM. Tris-HCl (pH 6.8), 10% glycerol and 2% sodium dodecyl sulfate (SDS). Protein concentration was determined using the BCA assay kit (Pierce, Rockford, IL, USA). Twenty micrograms of total proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (Tris-Glycine gels, Invitrogen Life Technologies), and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% non-fat dry milk, washed in TBST buffer, probed with the primary antibody, washed and incubated with horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences Corp., Piscataway, NJ, USA). For detection, enhanced chemiluminescence was carried out using the ECL kit (Amersham Biosciences Corp.). The antibodies used were: Cx43, p21 and p53 (all from Cell Signaling Technology, Beverly, MA, USA). The membranes were also probed with GAPDH antibody (Abcam Limited, Cambridge, UK) as loading control.
Scrape-loading/dye transfer assay Gap junctional intercellular communication was assayed by scrape-loading/dye transfer (el-Fouly et al., 1987) . Confluent cells grown in six-well culture plates were rinsed with HBSS (with calcium and magnesium), scraped with a surgical blade in the presence of 5 mg/ml Lucifer Yellow (Sigma) and incubated in the dye for 2 min. Cells were washed with HBSS again followed by addition of serum-free medium. Lucifer Yellow transfer was examined by fluorescence microscopy.
Immunofluorescence Confluent cells were washed with cold phosphate-buffered saline (PBS) and fixed with cold methanol for 15 min. Following PBS washes, cells were blocked with 5% bovine serum albumin (BSA) plus 0.2% Triton X-100 for 90 min at room temperature, incubated with Cx43 antibody (SigmaAldrich) in 1% BSA overnight at 41C, washed and incubated with Alexa Fluor 594 goat anti-rabbit antibody (Invitrogen) for 1 h.
